Drug discovery, redefined by computation.
Axia Discovery combines physics-based molecular simulation, generative AI, and multi-omics data to identify and validate novel drug candidates — faster, and with greater precision than conventional approaches.
End-to-end computational drug discovery
From target to candidate, our integrated platform compresses timelines while elevating the quality of every decision.
Target Identification
Genomics · ProteomicsMulti-omics and network-biology integration to prioritize disease-relevant receptor targets with high therapeutic confidence.
De Novo Design
Generative AI · De NovoGenerative AI designs novel cyclic-peptide binders from scratch against a chosen target — ownable compositions of matter, not library hits.
Physics-Based Simulation
Physics-BasedPhysics-based molecular simulation models how candidates bind and behave, prioritizing the most selective, highest-quality designs before synthesis.
Selectivity by Design
SelectivityCandidates are engineered to discriminate the intended target from its closest receptor relatives — selectivity built in from the first design.
Developability
PK/PD · SafetyComputational assessment of developability, PK, and safety liabilities early in the campaign — surfacing risk before the wet lab.
Lead Refinement
Iterative DesignIterative design-and-assess cycles refine each candidate toward its target product profile.
Three patent-pending radioligand therapy programs
De novo-designed cyclic peptides, led by oncology radioligand therapy. CNS, cardiometabolic, and renal programs are listed in the full pipeline. 11 U.S. provisional patent applications filed 2026.
In-silico-designed, wet-lab validation underway · patent pending · PCT international filings anticipated · Pipeline subject to change
Rigorous methodology, measurable outcomes
Physics-based simulation and generative AI, applied with discipline at every step — novel candidates designed in silico, with wet-lab validation underway.
Ready to accelerate your drug discovery program?
Whether you're seeking a computational co-development partner, licensing opportunities, or looking to advance a difficult target — let's talk.